GC Green Cross Approves Phase 2 Clinical Trial of Influenza Vaccine in the Elderly … Proximity to Commercialization



[ad_1]

<img src = "http://img.etnews.com/photonews/1807/1095170_20180726151107_817_0001.jpg" alt = "GC Green Cross said on February 26 that it has been approved by the Food and Drug Administration for the second phase of clinical trials of high-dose influenza vaccine 4 "GC3114"

GC3114, It is expected that it will have a prevention effect much higher for older influenza that has a weaker immune system because the content is four times higher Generic influenza vaccines respond to an immunity rate of 70 to 90% in healthy adults, but over the age of 65 are only 17-53% effective.

At present, the vaccine for the elderly only has a commercial version of the trivalent vaccine that prevents three types of influenza worldwide

If society succeeds in developing a vaccine against High dose four-dose flu, GC Green Cross will develop a range of flu shots comparable to that of a leading global vaccine manufacturer. He is equipped. GC Green Cross, which successfully marketed Korea's first influenza vaccine in 2009, has developed 10 types of influenza vaccines, including 3 and 4 seasonal flu vaccines, pandemic vaccines and pandemic vaccines. It's a product a year.

The company said: "The expansion of the product line is significant not only in terms of social aspects such as the effective prevention of influenza by age group, but also in terms of increasing global market share. "

] Jang Yoon-hyung, journalist in medicine / biotechnology [email protected]


"Nonsense! (19659009) function (f, b, e, v, n, t, s)
{if (f.fbq) returns; n = f.fbq = function () {n.callMethod?
n.callMethod.apply (n, arguments): n.queue.push (arguments)};
if (! f._fbq) f._fbq = n; n.push = n; n.loaded =! 0; n.version = 2.0 & # 39 ;;
n.queue = []; t = b.createElement (e); t.async =! 0;
t.src = v; s = b.getElementsByTagName (e) [0];
s.parentNode.insertBefore (t, s)} (window, document, & quot; script & # 39;
& # 39; https: //connect.facebook.net/en_US/fbevents.js&#39;);
fbq (& # 39 ;, & # 39; 199817140623212 & # 39;);
fbq ("track", "Pageview");
[ad_2]
Source link